CD133 regulates IL-1β signaling and neutrophil recruitment in glioblastoma

Molecules and Cells

Volumn 40, Issue 7, 2017, Pages 515-522

  Lee, Seon Yong ^a   Kim, Jun Kyum ^a   Jeon, Hee Young ^a   Ham, Seok Won ^a   Kim, Hyunggee ^a  

^a Korea University   (South Korea)

Author keywords

CD133; Glioblastoma; IL 1 signaling; Neutrophil; U87MG glioma cell

Indexed keywords

BETA ACTIN; CD133 ANTIGEN; CXCL3 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; CHEMOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CELL SELF-RENEWAL; CONTROLLED STUDY; ECTOPIC EXPRESSION; GENE EXPRESSION REGULATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE FUNCTION; MOUSE; NEUROPATHOLOGY; NEUTROPHIL; NEUTROPHIL RECRUITMENT; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; U87MG CELL LINE; ANIMAL; BAGG ALBINO MOUSE; BRAIN TUMOR; GENETICS; HEK293 CELL LINE; METABOLISM; NEUTROPHIL CHEMOTAXIS; NUDE MOUSE; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; UPREGULATION;

AC133 ANTIGEN; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHEMOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HEK293 CELLS; HUMANS; INTERLEUKIN-1BETA; MICE, INBRED BALB C; MICE, NUDE; NEUTROPHIL INFILTRATION; PROGNOSIS; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 85029477759     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2017.0089     Document Type: Article

References (31)

1. Brat, D.J., Castellano-Sanchez, A.A., Hunter, S.B., Pecot, M., Cohen, C., Hammond, E.H., Devi, S.N., Kaur, B., and Van Meir, E.G. (2004). Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res. 64, 920-927.
2. Brescia, P., Richichi, C., and Pelicci, G. (2012). Current strategies for identification of glioma stem cells: adequate or unsatisfactory?. J. Oncol. 2012, 376894.
3. Brescia, P., Ortensi, B., Fornasari, L., Levi, D., Broggi, G., and Pelicci, G. (2013). CD133 is essential for glioblastoma stem cell maintenance. Stem Cells 31, 857-869.
4. Chen, K., Huang, Y.H. and Chen, J.L. (2013). Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta. Pharmacol. Sin. 34, 732-740.
5. Eash, K.J., Greenbaum, A.M., Gopalan, P.K., and Link, D.C. (2010). CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J. Clin. Invest. 120, 2423-2431.
6. Eramo, A., Ricci-Vitiani, L., Zeuner, A., Pallini, R., Lotti, F., Sette, G., Pilozzi, E., Larocca, L.M., Peschle, C., and De Maria, R. (2006). Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 13, 1238-1241.
7. Griguer, C.E., Oliva, C.R., Gobin, E., Marcorelles, P., Benos, D.J., Lancaster, J.R. Jr., and Gillespie, G.Y. (2008). CD133 is a marker of bioenergetic stress in human glioma. PloS One 3, e3655.
8. Han, M., Guo, L., Zhang, Y., Huang, B., Chen, A., Chen, W., Liu, X., Sun, S., Wang, K., Liu, A., et al. (2016). Clinicopathological and prognostic significance of CD133 in glioma patients: A meta-analysis. Mol. Neurobiol. 53, 720-727.
9. Highfill, S.L., Cui, Y., Giles, A.J., Smith, J.P., Zhang, H., Morse, E., Kaplan, R.N., and Mackall, C.L. (2014). Disruption of CXCR2- mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6, 237ra67.
10. Kaiser, J. (2015). The cancer stem cell gamble. Science 347, 226-229.
11. Klonisch, T., Wiechec, E., Hombach-Klonisch, S., Ande, S.R., Wesselborg, S., Schulze-Osthoff, K., and Los, M. (2008). Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Medicine 14, 450-460.
12. Lathia, J.D., Mack, S.C., Mulkearns-Hubert, E.E., Valentim, C.L., and Rich, J.N. (2015). Cancer stem cells in glioblastoma. Genes Dev. 29, 1203-1217.
13. Omuro, A., and DeAngelis, L.M. (2013). Glioblastoma and other malignant gliomas: a clinical review. JAMA 310, 1842-1850.
14. Pallini, R., Ricci-Vitiani, L., Montano, N., Mollinari, C., Biffoni, M., Cenci, T., Pierconti, F., Martini, M., De Maria, R., and Larocca, L.M. (2011). Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer 117, 162-174.
15. Park, E.K., Lee, J.C., Park, J.W., Bang, S.Y., Yi, S.A., Kim, B.K., Park, J.H., Kwon, S.H., You, J.S., Nam, S.W., et al. (2015). Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Cell Death Dis. 6, e1964.
16. Pearson, M.J., Philp, A.M., Heward, J.A., Roux, B.T., Walsh, D.A., Davis, E.T., Lindsay, M.A., and Jones, S.W. (2016). Long intergenic noncoding RNAs mediate the human chondrocyte inflammatory response and are differentially expressed in osteoarthritis cartilage. Arthritis Rheumatol. 68, 845-856.
17. Rempel, S.A., Dudas, S., Ge, S., and Gutierrez, J.A. (2000). Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin. Cancer Res. 6, 102-111.
18. Sharma, V., Dixit, D., Ghosh, S., and Sen, E. (2011a). COX-2 regulates the proliferation of glioma stem like cells. Neurochem. Int. 59, 567-571.
19. Sharma, V., Dixit, D., Koul, N., Mehta, V.S., and Sen, E. (2011b). Ras regulates interleukin-1beta-induced HIF-1alpha transcriptional activity in glioblastoma. J. Mol. Med. 89, 123-136.
20. Soeda, A., Park, M., Lee, D., Mintz, A., Androutsellis-Theotokis, A., McKay, R.D., Engh, J., Iwama, T., Kunisada, T., Kassam, A.B., et al. (2009). Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28, 3949-3959.
21. Steele, C.W., Karim, S.A., Leach, J.D., Bailey, P., Upstill-Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. (2016). CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29, 832-845.
22. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550.
23. Sunkin, S.M., Ng, L., Lau, C., Dolbeare, T., Gilbert, T.L., Thompson, C.L., Hawrylycz, M., and Dang, C. (2013). Allen Brain Atlas: an integrated spatio-temporal portal for exploring the central nervous system. Nucleic Acids Res. 41, D996-D1008.
24. Wang, G., Lu, X., Dey, P., Deng, P., Wu, C.C., Jiang, S., Fang, Z., Zhao, K., Konaparthi, R., Hua, S., et al. (2016). Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. 6, 80-95.
25. Wei, Y., Jiang, Y., Zou, F., Liu, Y., Wang, S., Xu, N., Xu, W., Cui, C., Xing, Y., Liu, Y., et al. (2013). Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc. Natl. Acad. Sci. USA 110, 6829-6834.
26. Wu, Y. and Wu, P.Y. (2009). CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 18, 1127-1134.
27. Yeung, Y.T., McDonald, K.L., Grewal, T., and Munoz, L. (2013). Interleukins in glioblastoma pathophysiology: implications for therapy. Br. J. Pharmacol. 168, 591-606.
28. Zahreddine, H., and Borden, K.L. (2013). Mechanisms and insights into drug resistance in cancer. Front. Pharmacol. 4, 28.
29. Zeppernick, F., Ahmadi, R., Campos, B., Dictus, C., Helmke, B.M., Becker, N., Lichter, P., Unterberg, A., Radlwimmer, B., Herold-Mende, C.C., et al. (2008). Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14, 123-129.
30. Zhang, L., Zhang, L., Li, H., Ge, C., Zhao, F., Tian, H., Chen, T., Jiang, G., Xie, H., Cui, Y., et al. (2016). CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation. Sci. Rep. 6, 27426.
31. Zhu, L., Finkelstein, D., Gao, C., Shi, L., Wang, Y., Lopez-Terrada, D., Wang, K., Utley, S., Pounds, S., Neale, G., et al. (2016). Multi-organ mapping of cancer risk. Cell 166, 1132-1146.